Globus Medical

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Globus Medical achieves record revenue, plans NuVasive merger

Globus Medical (GMED) delivered strong financial performance in 2022, with record revenue and notable growth across key segments.
The planned merger with NuVasive and focus on product innovation position the company for future success and market leadership.
Challenges such as retaining talent and addressing international market dynamics require strategic solutions for sustained growth.
Opportunities lie in diversifying revenue streams, expanding product offerings, and leveraging international markets for continued success.

Globus Medical (GMED) reports record Q1 sales, eyes growth opportunities

Globus Medical (GMED) delivered a strong Q1 performance with record sales and profit growth, driven by strategic initiatives and market demand. While facing challenges like merger delays and potential competition, the company's focus on innovation, technology leadership, and market recognition positions it well for sustained growth and success.

Globus Medical posts record Q2 sales, eyes growth through innovation

Globus Medical delivered a strong Q2 performance with record sales and profitability, driven by innovation and market expansion.
While facing integration challenges post-merger, the company's focus on growth segments and product innovation positions it well for future success.
Opportunities lie in expanding market presence, driving innovation, and capitalizing on technological advancements to sustain growth momentum.

Globus Medical reports record Q3 sales, eyes growth opportunities

Globus Medical's Q3 performance reflects robust sales growth, steady EPS, and progress towards revenue targets, underpinned by innovative product launches and strategic integration efforts.
While facing challenges in hiring and cost synergies, the company's focus on talent acquisition, cost management, and segment-specific strategies positions them well for future growth.
Opportunities lie in new product launches, technological advancements, and streamlined operations through sales force integration, indicating a promising trajectory for Globus Medical's continued success.

Globus Medical (GMED) reports record revenue in 2023, eyes growth amid challenges

Globus Medical (GMED) delivered strong financial results in 2023, driven by the NuVasive merger, with a focus on integration and innovation. While facing challenges from dissynergies and market competition, GMED is poised to capitalize on growth opportunities through strategic initiatives and product launches.

Globus Medical excels in Q1 2024, eyes Enabling Technologies growth

Globus Medical's Q1 2024 showcased exceptional sales growth, margin improvement, and strategic initiatives. Despite challenges in integration and product rollout timing, the company is poised for long-term success. Opportunities in Enabling Technologies and cost leverage position Globus for continued growth.

Globus Medical excels in Q3, eyes margin improvement strategies

Globus Medical's Q3 performance reflects strong financial results, innovation, and market expansion. While challenges in margin improvement persist, the company's strategic focus on cost optimization and product development sets the stage for continued growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AUDUBON, Pa., July  21, 2020  (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the first quarter ended June 30, 2020 after the market close on Wednesday, August 5, 2020. A copy of the release will be available on the Globus Medical website at www.globusmedical.com/investors.

Globus Medical Schedules Second Quarter 2020 Earnings Release and Conference Call

Cerner

Health Catalyst Inc

Big data is becoming a big factor in the healthcare industry.

3 Big Data Health Stocks to Watch in 2020

ABB Ltd.

AeroVironment

Global X Robotics & Artificial Intelligence ETF

FLIR Systems

iRobot

Intuitive Surgical

Stereotaxis Inc

Trimble

Robotics stocks offer multi-decade growth potential. These 10 stocks offer some of the best exposure to this attractive trend.

10 Robotics Stocks on the Technological Cutting Edge

Globus Medical (GMED) notes that the U.S. spine business bottomed in the first full week of April, witnessing a decline of about 70% from its pre-COVID 19 pace.

Globus Medical Faces Business Loss Amid Coronavirus Crisis

Globus Medical, Inc. (GMED) CEO Dave Demski on Q1 2020 Results - Earnings Call Transcript

Globus Medical (GMED) witnesses around $20 million of COVID-19 related adverse impact on its Q1 sales.

Globus Medical (GMED) Misses on Q1 Earnings and Revenues

The medical-device maker's revenue and earnings fell below Wall Street expectations.

Why Globus Medical Missed Q1 Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of -27.50% and -4.65%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical (GMED) Lags Q1 Earnings and Revenue Estimates

Teladoc

Healthcare stocks are in the spotlight as the coronavirus brings to light the importance of collecting data and using it to predict outcomes.

3 Healthcare Stocks to Buy for AI and Big Data

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock?

Why Is Globus Medical (GMED) Down 28.9% Since Last Earnings Report?

Globus Medical Inc’s (NYSE: GMED) shares have declined around 33% from their year-end 2019 high, and the company has a strong balance sheet that can be used to acquire assets at depressed values, according to BTIG.

BTIG Buys Into Globus Medical's Longer-Term Vision

AUDUBON, Pa., March  11, 2020  (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the Board of Directors authorized the repurchase of $200 million of the Company’s common stock.

Globus Medical Announces $200 Million Share Repurchase Program

Globus Medical (GMED) registers impressive growth within U.S. Spine on record recruiting of competitive representatives in Q4.

Globus Medical (GMED) Lags Q4 Earnings, Beats on Revenues

Globus Medical, Inc. (GMED) CEO David Demski on Q4 2019 Results - Earnings Call Transcript

Globus Medical (GMED) delivered earnings and revenue surprises of -5.77% and 0.32%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical (GMED) Misses Q4 Earnings Estimates

HEDRON IA is the only commercially available 3D printed integrated Anterior Lumbar Interbody Fusion (ALIF) spacer with anchor technology HEDRON IA is the only commercially available 3D printed integrated Anterior Lumbar Interbody Fusion (ALIF) spacer with anchor technology

Globus Medical Announces First Case with Next Generation 3D Printed Spine Implant

Globus Medical (GMED) delivers solid spine sales globally. Enabling Technologies too rides high on the rising uptake of ExcelsiusGPS platform.

Globus Medical Gains From International Spine Arm, Innovation

A recent stock price dip gives buy-and-hold investors an attractive entry price.

Why You Should Own This Medical Device Company in 2020

Per Globus Medical (GMED), it ends 2019 on a promising note with an apparently solid robotic pipeline and a speedy competitive recruiting.

Globus Medical Stock Up on Solid '19 Preliminary Results

Investors continue to be optimistic about Globus Medical (GMED) on its stellar segmental performance.

Here's Why You Should Hold on to Globus Medical Stock for Now

Globus Medical's (GMED) U.S. Spine business is securing a market share on the back of competitive representative recruiting and an implant pull-through from ExcelsiusGPS installations.

Globus Medical Rides on New Product Menu, U.S. Spine Business

AUDUBON, Pa., Dec.  13, 2019  (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the appointment of Robert Douglas to the Company’s Board of Directors, and the departure of Board member Kurt Wheeler, effective December 11, 2019.   Mr. Wheeler has assumed a role that precludes him from serving on public company Boards. 

Globus Medical Announces Board of Director Addition and Departure

Globus Medical (GMED) is optimistic about sustaining its growth momentum on recent positive developments.

Globus Medical Hits 52-Week High: What's Driving the Stock?

Why Is Globus Medical (GMED) Up 3.9% Since Last Earnings Report?

Align Technology

Edwards Lifesciences

LeMaitre Vascular

QuidelOrtho Corp

Repligen

ResMed

Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs.

News for Globus Medical Stock (GMED)